2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-136855
    MitoPBN 652968-37-1
    MitoPBN is a AMPK/SIRT3/PGC-1α axis modulator, reactive oxygen species scavenger and mitochondrial function enhancer. MitoPBN increases the phosphorylation level of AMPK, restores SIRT3 expression and reverses the down-regulation of PGC-1α, thereby promoting mitochondrial biogenesis. MitoPBN regulates glucose metabolism, reduces blood glucose by inhibiting hepatic gluconeogenesis and increasing hepatic glucose uptake, while scavenging mitochondrial superoxide anion/hydrogen peroxide, maintaining membrane potential and increasing ATP production. MitoPBN also reduces cell apoptosis, improves sperm motility, survival rate and membrane integrity, but may induce reductive stress in cryopreserved sperm at high concentrations. MitoPBN is widely applicable to research related to diabetes and type 2 diabetes.
    MitoPBN
  • HY-137959
    Telmisartan acyl-β-D-glucuronide 250780-40-6
    Telmisartan acyl-β-D-glucuronide is an acyl-β-D-glucuronide and a metabolite of Telmisartan (HY-13955). Telmisartan acyl-β-D-glucuronide can be converted back to Telmisartan upon incubation with Glucuronidase. Partial acyl migration of Telmisartan acyl-β-D-glucuronide occurs under physiological conditions.
    Telmisartan acyl-β-D-glucuronide
  • HY-138937
    NDB 1660153-08-1 98.36%
    NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research.
    NDB
  • HY-139078
    Furosine dihydrochloride 157974-36-2
    Furosine dihydrochloride, an amino acid derivative, is an important chemical marker of early-stage Maillard reactions. Furosine dihydrochloride is closely related to a variety of diseases such as diabetes.
    Furosine dihydrochloride
  • HY-139284
    C24:1 Dihydro 1-deoxyceramide (m18:0/24:1) 1246298-60-1 99.0%
    C24:1 Dihydro 1-deoxyceramide (m18:0/24:1) (C24:1 Deoxy dihydroceramide) is a lipid molecule, which is composed of a long-chain fatty acid (24:1) and a 1-deoxysphingoid backbone. Deoxyceramide accumulates under the conditions of obesity and type 2 diabetes (T2D). Deoxyceramide is unable to be further metabolized to more complex sphingolipid, and is toxic when accumulates in the body. Deoxyceramide increases in differentiated adipocytes in vitro.
    C24:1 Dihydro 1-deoxyceramide (m18:0/24:1)
  • HY-141508
    Flazin 100041-05-2 99.64%
    Flazin is a non-enzymatic protein glycation inhibitor, also inhibits peroxynitrite (ONOO-), with an IC50 value of 85.31 μM for bovine serum albumin (BSA) glycation and an EC50 value of 71.99 μM for ONOO-. Flazin can be used for researching diabetes and neuronal disorders. Flazin also can used as a lipid droplet (LD) regulator against lipid disorders, and a xanthine oxidase (XOD) inhibitor.
    Flazin
  • HY-142026
    Vitisin A 142449-89-6
    Vitisin A ((+)-Vitisin A) is an orally active natural product with multiple pharmacological activities including anti-inflammatory, anti-tumor, anti-oxidant, anti-pathogenic microorganism, hypoglycemic and lipid-regulating, anti-osteoporotic, neuroprotective and cardiovascular protective effects. Vitisin A exhibits inhibitory effects on human AChE and MAO-B with IC50 values of 1.29 µM and 4.94 µM, respectively. Vitisin A inhibits the ERK, MAPK, NF-κB, STAT1, HMGCR and TRAF6 pathways, downregulates the related phosphorylation and protein expression, while activates the Nrf2/HO-1 pathway and upregulates p21 expression. Vitisin A induces tumor cell apoptosis and cell cycle arrest, inhibits adipogenesis and lipid accumulation, while alleviates oxidative stress, suppresses inflammatory responses, blocks hepatic fibrosis, Cuproptosis and cholesterol synthesis, and increases the expression levels of central BDNF and TrkB. Vitisin A can be used in the research of tumors, infectious diseases, metabolic diseases, bone and joint diseases, liver diseases, skin injuries, as well as neurodegenerative and cognitive dysfunction-related diseases.
    Vitisin A
  • HY-143469
    NPP1-IN-1 2493063-65-1 99.56%
    NPP1-IN-1 is a potent NPP inhibitor with IC50s of 0.15 μM and 40 μM for NPP1 and NPP3, respectively.
    NPP1-IN-1
  • HY-143613
    THR-β agonist 2 2440027-77-8 99.31%
    THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3).
    THR-β agonist 2
  • HY-144270
    Glucosylceramide synthase-IN-3 3029827-91-3 99.11%
    Glucosylceramide synthase-IN-3 (compound BZ1) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 16 nM for human GCS.Glucosylceramide synthase-IN-3 can be used for Gaucher's disease research.
    Glucosylceramide synthase-IN-3
  • HY-144377
    RXR antagonist 1 3010910-40-1 99.94%
    RXR antagonist 1 (compound 6a) is a retinoid X receptor (RXR) modulator. RXR antagonist 1 shows potent RXR-antagonistic activity, with a pA2 of 8.06. RXR antagonist 1 can be used for type 2 diabetes research.
    RXR antagonist 1
  • HY-145534
    trans-2-Octenoyl-L-carnitine 152064-94-3 99.92%
    trans-2-Octenoyl-L-carnitine (CAR 8:1; C8:1 Carnitine; L-Carnitine trans-2-octenoyl ester) is a medium-chain monounsaturated acylcarnitine that rarely occurs in healthy humans, and it is a fatty acid oxidation-related metabolite associated with gut microbiota-host co-metabolism. trans-2-Octenoyl-L-carnitine can serve as an analytical reference standard for qualitative and quantitative detection of carnitine metabolites in scientific research, particularly in human urine samples.
    trans-2-Octenoyl-L-carnitine
  • HY-147108
    Mitochondria degrader-1 2241669-05-4
    Mitochondria degrader-1 (example 5) is a potent mitochondria degrader. Mitochondria degrader-1 induces the degradation of the injured mitochondria by the autophagy mechanism. Mitochondria degrader-1 can be used for the research of neurodegenerative disease, cancer, inflammatory disease, age-related disease, metabolic disease, mitochondrial disease or Down's disease.
    Mitochondria degrader-1
  • HY-147625
    GLP-1R agonist 12 2765595-19-3
    GLP-1R agonist 12 (Compound 123) is an agonist of glucagon-like peptide-1 receptors (GLP-1R). GLP-1R agonist 12 can be used for diabetes research.
    GLP-1R agonist 12
  • HY-147705
    PPARγ phosphorylation inhibitor 1 2882975-84-8 99.81%
    PPARγ phosphorylation inhibitor 1 (Compound 10) is a potent PPARγ binder with the IC50 of 24 nM. PPARγ phosphorylation inhibitor 1 inhibits CDK5-mediated phosphorylation of PPARγ Ser273 with the IC50 of 160 nM. PPARγ phosphorylation inhibitor 1 displays negligible PPARγ agonism in a reporter gene assay. Antidiabetic effects.
    PPARγ phosphorylation inhibitor 1
  • HY-147976
    Glucocerebrosidase-IN-1 2279945-76-3 99.65%
    Glucocerebrosidase-IN-1 (compound 11a) is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC50 of 29.3 μM and a Ki of 18.5 μM. Glucocerebrosidase-IN-1 can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD).
    Glucocerebrosidase-IN-1
  • HY-148329
    GSK3-IN-2 380450-97-5 99.87%
    GSK3-IN-2 (compound 8) is a potent GSK3 inhibitor.
    GSK3-IN-2
  • HY-148694
    ISX-3 912789-08-3 99.68%
    ISX-3 is a potent anti-adipogenic and pro-osteogenic agent. ISX-3 increases the expression of PPARγ. ISX-3 has the potential for the research of osteopenia and osteoporosis.
    ISX-3
  • HY-149207
    Tyrosinase-IN-11 240797-64-2 98.12%
    Tyrosinase-IN-11 is a potent tyrosinase inhibitor with IC50s of 50 nM and 64 nM for L-tyrosinase and L-dopa, respectively. Tyrosinase-IN-11 has significant antioxidant activity and low cytotoxicity. Tyrosinase-IN-11 has the potential for skin hyperpigmentation research.
    Tyrosinase-IN-11
  • HY-150019
    PI3K-IN-36 1401436-93-8 98.76%
    PI3K-IN-36 (compound A68) is a potent PI3K inhibitor. PI3K-IN-36 can be used in research of follicular lymphoma (FL).
    PI3K-IN-36
Cat. No. Product Name / Synonyms Application Reactivity